Wells Pharma is disrupting the $5.5B prefilled surgical IV bag and syringe market that has traditionally been produced in hospitals; by providing higher quality, better shelf life and reducing costs.
Wells Pharma provides hospitals and their patients with life-saving drugs when they need them most. We aim to help patients and healthcare facilities get their life-saving drugs as quickly and safely as possible, saving hospitals and surgery centers time and money.
REASONS TO INVEST
• BE PART OF THE SOLUTION: Wells Pharma delivers life-saving medications to Hospitals and Surgery Centers across the nation. Our products are cost-effective, saving Hospitals and Surgery Centers millions of dollars a year.
• JOIN THE TEAM: Wells Pharma has already made the investments to overcome the barriers to entry required to achieve success in this market. The Company is FDA Registered, licensed in 48 states, and has built out the infrastructure necessary for a competitive advantage. The Company's 2022 revenues were in excess of $7M and the Company will achieve $1.25M in gross revenue in January 2023 at a $15M run-rate and growing.
• EXPERIENCE MATTERS: Investing founders and our management team are experienced and have a proven track record of creating value for investors and have already raised over $18M.
LSE, Inc. (DBA Wells Pharmaceuticals, "Wells Pharma") is offering 1,000,000 Class A1 common shares, non-voting at $5.00 per share with a pre-money valuation of $34M.